Semaxanib

CAS No. 194413-58-6

Semaxanib ( SU5416 )

Catalog No. M13045 CAS No. 194413-58-6

Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 37 In Stock
10MG 30 In Stock
25MG 48 In Stock
50MG 71 In Stock
100MG 111 In Stock
200MG 174 In Stock
500MG 341 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Semaxanib
  • Note
    Research use only, not for human use.
  • Brief Description
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM.
  • Description
    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SU5416
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2/Flk1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    194413-58-6
  • Formula Weight
    238.28
  • Molecular Formula
    C15H14N2O
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 2 mg/mL (8.39 mM); DMSO: 22 mg/mL (92.32 mM)
  • SMILES
    CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fong TA, et al. Y Res, 1999, 59(1), 99-106.
molnova catalog
related products
  • Veratric acid

    Veratric acid plays an important role in producing antibiotics and various dyes.

  • Acrizanib

    Acrizanib (LHA510, LHA-510) is a novel potent, selective VEGFR-2 (KDR) inhibitor with IC50 of 17.4 nM in cell-based assays.

  • FTI 277 hydrochlorid...

    FTI 277 hydrochloride is an effective and specific farnesyltransferase (FTase) inhibitor (IC50: 500 pM); this selectivity is about 100-fold than the closely related GGTase I.